Low interferon gamma producers are better treatment responders. A two years 
follow-up of interferon beta treated multiple sclerosis patients

Petereit, H.F.; Nolden, S.; Schoppe, S.; Bamborschke, Stefan; Pukrop, R.; Heiss, Wolf-Dieter

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Low interferon gamma producers are better treatment responders. A two years follow-up of interferon beta treated multiple sclerosis patients

MPS-Authors

/persons/resource/persons147188

Heiss, Wolf-Dieter
Wolf-Dieter Heiss, Emeriti, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Petereit, H., Nolden, S., Schoppe, S., Bamborschke, S., Pukrop, R., & Heiss, W.-D. (2002). Low interferon gamma producers are better treatment responders. A two years follow-up of interferon beta treated multiple sclerosis patients. Multiple Sclerosis, 8(6), 492-494.

Cite as: https://hdl.handle.net/11858/00-001M-0000-0026-D689-0

Abstract

As response to interferon beta (IFNB) treatment a 50% reduction of the mean relapse rate compared to pretreatment values has been reported. However, individual responses vary considerably, ranging from no reduction in exacerbation frequency to complete suppression of relapses for at least two years. At the moment valid predictors for IFNB response are lacking. Here we present a prospective evaluation of 33 patients with primary relapsing multiple sclerosis, who were followed for two years of IFNB treatment. A low interferon gamma (IFG) production before treatment predicted a two-year term without exacerbations in 68.8% of cases correctly, whereas a high pretreatment IFG production implied the risk of at least one relapse in the first two years in 70.6%. These preliminary results encourage further evaluation of IFG as predictor of an IFNB treatment response.